Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | September 06, 2024 | September 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date September 06, 2024 · Filed September 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,651 |
Reported balance
After 2024-09-06 transaction · row 1
1 source rowRow 1 · 2024-09-06 · Gift · Disposed 230,000 · Balance 35,651 |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2022 GRAT | 0 |
Reported balance
After 2024-09-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-09-06 · Gift · Disposed 302,179 · Balance 0 F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2024 GRAT | 419,574 |
Reported balance
After 2024-09-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-06 · Gift · Acquired 419,574 · Balance 419,574 F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Ayers Family Trust | 122,605 |
Reported balance
After 2024-09-06 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-09-06 · Gift · Acquired 112,605 · Balance 122,605 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2017 Filed Aug 17, 2017 01:32 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 2,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-032509 · doc1.xml · derivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,000 Underlying: Common Stock · 2,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 14, 2017 Filed Aug 17, 2017 01:32 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-032509 · doc1.xml · derivative · entry 13 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 14, 2017 Filed Aug 17, 2017 01:32 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,000 | $38.80 | $77,590.00 |
DisclosureSEC source: 0001140361-17-032509 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2017 Filed Aug 17, 2017 01:32 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 18,000 | $154.91 | $2,788,336.80 |
DisclosureSEC source: 0001140361-17-032509 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,034 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $154.80 to a high of $155.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2017 Filed Aug 17, 2017 01:32 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-17-032509 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 3,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-031210 · doc1.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 3,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 17,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-031210 · doc1.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,000 Underlying: Common Stock · 17,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 3,000 | $38.80 | $116,385.00 |
DisclosureSEC source: 0001140361-17-031210 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 17,000 | $154.54 | $2,627,183.40 |
DisclosureSEC source: 0001140361-17-031210 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,022,034 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $154.18 to a high of $154.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 17,000 | $38.80 | $659,515.00 |
DisclosureSEC source: 0001140361-17-031210 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,039,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2017 Filed Aug 9, 2017 22:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 2,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-030931 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,000 Underlying: Common Stock · 2,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 08, 2017 Filed Aug 9, 2017 22:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-030931 · doc1.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 08, 2017 Filed Aug 9, 2017 22:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,000 | $38.80 | $77,590.00 |
DisclosureSEC source: 0001140361-17-030931 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,022,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2017 Filed Aug 9, 2017 22:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 6,500 | $155.81 | $1,012,782.55 |
DisclosureSEC source: 0001140361-17-030931 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,034 F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $155.56 to a high of $156.14 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 08, 2017 Filed Aug 9, 2017 22:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 11,500 | $154.89 | $1,781,177.50 |
DisclosureSEC source: 0001140361-17-030931 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,534 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $154.55 to a high of $155.54 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 08, 2017 Filed Aug 9, 2017 22:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-17-030931 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 40 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2017. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:40 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 15,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-023350 · doc1.xml · derivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,000 Underlying: Common Stock · 15,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:40 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 13,000 | $167.82 | $2,181,643.10 |
DisclosureSEC source: 0001140361-17-023350 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,994 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $167.34 to a high of $168.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:40 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 15,000 | $38.80 | $581,925.00 |
DisclosureSEC source: 0001140361-17-023350 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,032,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 20,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-019820 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,000 Underlying: Common Stock · 20,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-019820 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 10,800 | $163.28 | $1,763,380.80 |
DisclosureSEC source: 0001140361-17-019820 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014,994 F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $163.04 to a high of $163.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 6,200 | $162.28 | $1,006,154.60 |
DisclosureSEC source: 0001140361-17-019820 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,028,794 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $161.95 to a high of $162.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 20,000 | $38.80 | $775,900.00 |
DisclosureSEC source: 0001140361-17-019820 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 10,000 | $162.31 | $1,623,092.00 |
DisclosureSEC source: 0001140361-17-019820 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014,994 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $161.55 to a high of $162.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 11, 2017 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 10,000 | $38.80 | $387,950.00 |
DisclosureSEC source: 0001140361-17-019820 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed Jun 1, 2017 21:39 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 20,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-023349 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,000 Underlying: Common Stock · 20,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 10, 2017 Filed Jun 1, 2017 21:39 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-023349 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 10, 2017 Filed Jun 1, 2017 21:39 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 10,800 | $163.28 | $1,763,380.80 |
DisclosureSEC source: 0001140361-17-023349 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,017,994 F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $163.04 to a high of $163.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F7 · balance_after: Amendment filed due to scrivener's error in the calculation of the number of shares held at the completion of the transactions. Read SEC document |
| May 10, 2017 Filed Jun 1, 2017 21:39 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 6,200 | $162.28 | $1,006,154.60 |
DisclosureSEC source: 0001140361-17-023349 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,028,794 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $161.95 to a high of $162.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed Jun 1, 2017 21:39 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 20,000 | $38.80 | $775,900.00 |
DisclosureSEC source: 0001140361-17-023349 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed Jun 1, 2017 21:39 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 10,000 | $162.31 | $1,623,092.00 |
DisclosureSEC source: 0001140361-17-023349 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014,994 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $161.55 to a high of $162.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed Jun 1, 2017 21:39 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 10,000 | $38.80 | $387,950.00 |
DisclosureSEC source: 0001140361-17-023349 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2017 Filed May 8, 2017 22:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 30,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-018919 · doc1.xml · derivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 30,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 05, 2017 Filed May 8, 2017 22:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 26,000 | $160.61 | $4,175,938.00 |
DisclosureSEC source: 0001140361-17-018919 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014,994 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $160.40 to a high of $160.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 05, 2017 Filed May 8, 2017 22:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 30,000 | $38.80 | $1,163,850.00 |
DisclosureSEC source: 0001140361-17-018919 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 47 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2017. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 50,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 50,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016, The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 2,286 | Not disclosed Strike: $43.71 | Not disclosed |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,286 shares Expires 2019-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 1,143 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2017, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,205 | $142.84 | $457,808.29 |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,947 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $142.80 to a high of $143.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 31,795 | $142.55 | $4,532,326.38 |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014,152 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $141.80 to a high of $142.795 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 50,000 | $38.80 | $1,939,750.00 |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,045,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,286 | $43.71 | $99,921.06 |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 1,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,708 Underlying: Common Stock · 1,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F6 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 2,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,482 Underlying: Common Stock · 2,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014 and has been adjusted to reflect the Stock Split. F6 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014 and has been adjusted to reflect the Stock Split. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 2,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,642 Underlying: Common Stock · 2,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vested in five equal annual installments, beginning February 14, 2013. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F6 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vested in five equal annual installments, beginning February 14, 2013. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vested in five equal annual installments, beginning February 14, 2013. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706 Underlying: Common Stock · 706 shares Expires 2027-02-13 F6 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 110,211 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,211 Underlying: Common Stock · 110,211 shares Expires 2027-02-13 F6 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 3,159 | $141.60 | $447,314.40 |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 993,661 F1 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008017 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.